Samsung BioLogics Co Ltd

207940

Company Profile

  • Business description

    Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2024, Samsung Biologics had a total production capacity of 754,000 liters, one of the largest in the world. Its CDMO services account for 66.2% of its total revenue. The balance comes from subsidiary Samsung Bioepis, acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.

  • Contact

    125, Cheomdan-daero
    Yeonsu-gu
    Incheon
    KOR

    https://www.samsungbiologics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    5,011

Stocks News & Analysis

stocks

The best way to get rich and retire early

This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks

Investors too optimistic about ASX growth story

Investors have gotten ahead of themselves with shares trading at a 94% premium to fair value.
stocks

Stellar growth from ASX retailer but markets still too optimistic

This Australian success story looks set to face profit margin compression from the scariest of competitors.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,103.1047.20-0.52%
CAC 407,793.2639.840.51%
DAX 4024,200.81176.030.73%
Dow JONES (US)44,458.61483.521.10%
FTSE 1009,168.3820.570.22%
HKSE25,613.67643.992.58%
NASDAQ21,681.90296.501.39%
Nikkei 22543,274.67556.501.30%
NZX 50 Index12,766.546.860.05%
S&P 5006,445.7672.311.13%
S&P/ASX 2008,827.1053.70-0.60%
SSE Composite Index3,683.4617.550.48%

Market Movers